| Literature DB >> 32645904 |
Gergő Porkoláb1, Mária Mészáros1, András Tóth1,2, Anikó Szecskó1, András Harazin1, Zsolt Szegletes1, Györgyi Ferenc3, András Blastyák4, Lajos Mátés4, Gábor Rákhely1,2, Mária A Deli1, Szilvia Veszelka1.
Abstract
Inefficient drug delivery across the blood-brain barrier (BBB) and into target cells in the brain hinders the treatment of neurological diseases. One strategy to increase the brain penetration of drugs is to use vesicular nanoparticles functionalized with multiple ligands of BBB transporters as vehicles. Once within the brain, however, drugs must also be able to reach their therapeutic targets in the different cell types. It is, therefore, favorable if such nanocarriers are designed that can deliver their cargo not only to brain endothelial cells, but to other cell types as well. Here, we show that alanineglutathione dual-targeting of niosomes enhances the delivery of a large protein cargo into cultured cells of the neurovascular unit, namely brain endothelial cells, pericytes, astrocytes and neurons. Furthermore, using metabolic and endocytic inhibitors, we show that the cellular uptake of niosomes is energy-dependent and is partially mediated by endocytosis. Finally, we demonstate the ability of our targeted nanovesicles to deliver their cargo into astroglial cells after crossing the BBB in vitro. These data indicate that dual-labeling of nanoparticles with alanine and glutathione can potentially be exploited to deliver drugs, even biopharmacons, across the BBB and into multiple cell types in the brain.Entities:
Keywords: alanine; astrocyte; blood–brain barrier; brain endothelial cell; glutathione; nanoparticle; neuron; neurovascular unit; niosome; pericyte
Year: 2020 PMID: 32645904 DOI: 10.3390/pharmaceutics12070635
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321